Avacta Group's (AVCT) "Buy" Rating Reiterated at Peel Hunt

Key Points

• Avacta Group's stock received a reaffirmed "buy" rating from Peel Hunt, with a target price of GBX 99, indicating a potential upside of 38.70% from its current trading price.
• The company has reported a negative EPS of GBX (4.46) for the last quarter, with analysts projecting an EPS of -9.90 for the current fiscal year.
• Avacta Group operates in biopharmaceuticals, focusing on innovative drug delivery methods through its proprietary pre|CISION® platform aimed at enhancing cancer therapeutics.

Avacta Group (LON:AVCT - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at Peel Hunt in a report issued on Monday, MarketBeat Ratings reports. They presently have a GBX 99 price objective on the biotechnology company's stock. Peel Hunt's price target indicates a potential upside of 38.70% from the company's current price.

Avacta Group Stock Performance

AVCT opened at GBX 71.38 on Monday. The company has a debt-to-equity ratio of 52.53, a current ratio of 1.29 and a quick ratio of 4.96. The stock has a market cap of £291.40 million, a P/E ratio of -406.70 and a beta of 1.12. Avacta Group has a 1-year low of GBX 26 and a 1-year high of GBX 75. The stock's 50 day simple moving average is GBX 54.80 and its 200 day simple moving average is GBX 41.78.

Avacta Group (LON:AVCT - Get Free Report) last released its earnings results on Tuesday, September 30th. The biotechnology company reported GBX (4.46) earnings per share (EPS) for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. As a group, equities analysts anticipate that Avacta Group will post -9.9011833 EPS for the current fiscal year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.